Clinical Trials
50 trialsCabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
National Cancer Institute (NCI)
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
M.D. Anderson Cancer Center
Lumed
University Hospital, Basel, Switzerland
LIBRETTO-001
Eli Lilly and Company
Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)
Shanghai Jiao Tong University School of Medicine
LIBRETTO-121
Eli Lilly and Company
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
Sanofi
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
MIMETIC
University Medical Center Groningen
ARROW
Hoffmann-La Roche
Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Mayo Clinic
Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer
M.D. Anderson Cancer Center
Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer
National Cancer Institute (NCI)
Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors
Boston Pharmaceuticals
177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer
University Hospital, Basel, Switzerland
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
H. Lee Moffitt Cancer Center and Research Institute
Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers
M.D. Anderson Cancer Center
Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer
National Cancer Institute (NCI)
Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer
University of Pennsylvania
Iodine I 131 in Treating Patients With Thyroid Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Vanderbilt-Ingram Cancer Center
Cinacalcet to Treat Familial Primary Hyperparathyroidism
National Institutes of Health Clinical Center (CC)
Thalidomide in Treating Patients With Thyroid Cancer
University of Kentucky
Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study
Massachusetts General Hospital
Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy
Massachusetts General Hospital
Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer
University of Washington
S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors
SWOG Cancer Research Network
Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer
National Cancer Institute (NCI)
A Study To Assess ZD6474 (ZACTIMAâ„¢) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
Sanofi
Capecitabine and Temozolomide for Neuroendocrine Cancers
Columbia University
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
National Cancer Institute (NCI)
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
University of Southern California
Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer
Yonsei University
Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer
National Cancer Institute (NCI)
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
Yale University
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
Delcath Systems Inc.
A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer
Amgen
Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer
National Cancer Institute (NCI)
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
National Cancer Institute (NCI)
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
National Cancer Institute (NCI)
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
National Cancer Institute (NCI)
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NGR-TNF in Treating Patients With Advanced Solid Tumors
European Organisation for Research and Treatment of Cancer - EORTC
Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors
Vanderbilt-Ingram Cancer Center
Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases
European Organisation for Research and Treatment of Cancer - EORTC
123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors
Vancouver Coastal Health
SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck
Case Comprehensive Cancer Center